ORIGINAL RESEARCH

Detection of SMN1 loss with PCR-based screening test

Nazarov VD1, Cherebillo CC1, Lapin SV1, Sidorenko DV1, Devyatkina YA1, Musonova AC1, Petrova TV2, Nikiforova AI2, Ivanova AV2
About authors

1 Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation, Russia

2 DNA-Technology LLC, Moscow, Russia

Correspondence should be addressed: Carina C. Cherebillo
6/8, Lva Tolstogo, Saint-Petersburg, 197022, Russia: ur.liam@olliberehc.k

About paper

Funding: All tests was provided by DNA-Technology LLC.

Author contribution: Nazarov VD, Lapin SV — concept; Sidorenko DV, Devyatkina YA, Musonova AC — investigation; Petrova TV, Nikiforova AI, Ivanova AV — methodology; Nazarov VD, Cherebillo CC — wrining, original draft preparation; Cherebillo CC, Lapin SV, Petrova TV, Nikiforova AI, Ivanova AV — writing, review & editing.

Compliance with ethical standards: this study was approved by the local Ethics Committee of the Pavlov First Saint Petersburg State Medical University (№ 274 from 26.06.2023). Written informed consent was obtained from all participants or their parents. The 1975 Declaration of Helsinki was rigorously adhered to secure the rights of the patients.

Received: 2023-05-30 Accepted: 2023-06-22 Published online: 2023-06-30
|
Fig. Schematic representation of SMN1 and SMN2 genotypes in each subgroup
Table 1. The number of copies SMN1 and SMN2 genes according to MLPA assay in Group 2
Table 2. Detection channels of PCR-products
Table 3. PCR cycling conditions
Table 4. Comparison of the results obtained by MLPA assay and PCR-based test assay technology in Group 1
Note: TP — true positive; FP — false positive; TN — true negative; FN — false negative.
Table 5. Comparison of the results obtained by MLPA assay and PCR-based test assay technology in Group 2
Note: TP — true positive; FP — false positive; TN — true negative; FN — false negative.